These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

797 related items for PubMed ID: 29411171

  • 1. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.
    Matsumoto H, Hiroe T, Morimoto M, Mimura K, Ito A, Akiyama H.
    Jpn J Ophthalmol; 2018 Mar; 62(2):144-150. PubMed ID: 29411171
    [Abstract] [Full Text] [Related]

  • 2. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
    Morimoto M, Matsumoto H, Mimura K, Akiyama H.
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1891-1897. PubMed ID: 28669041
    [Abstract] [Full Text] [Related]

  • 3. One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions.
    Matsumoto H, Mukai R, Kikuchi Y, Morimoto M, Akiyama H.
    Jpn J Ophthalmol; 2020 Mar; 64(2):203-209. PubMed ID: 32016666
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC, Lee DK, Kim SH, You YS, Kwon OW.
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Influence of submacular hemorrhage at baseline on the long-term outcomes of aflibercept treatment for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Hosokawa MM, Ouchi C, Shiode Y, Kimura S, Matoba R, Morita T, Morizane Y.
    Graefes Arch Clin Exp Ophthalmol; 2024 Oct; 262(10):3099-3107. PubMed ID: 38625447
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. RECURRENCE OF CHOROIDAL NEOVASCULARIZATION LESION ACTIVITY AFTER AFLIBERCEPT TREATMENT FOR AGE-RELATED MACULAR DEGENERATION.
    Wakazono T, Yamashiro K, Oishi A, Ooto S, Tamura H, Akagi-Kurashige Y, Hata M, Takahashi A, Tsujikawa A, Yoshimura N.
    Retina; 2017 Nov; 37(11):2062-2068. PubMed ID: 28590316
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes.
    Tanaka N, Azuma K, Aoki S, Kitamoto K, Ueda K, Fujino R, Inoue T, Obata R.
    Graefes Arch Clin Exp Ophthalmol; 2024 Jun; 262(6):1811-1818. PubMed ID: 38294513
    [Abstract] [Full Text] [Related]

  • 14. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK, Faber RT, Moe MC.
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [Abstract] [Full Text] [Related]

  • 15. Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration.
    Haga A, Kawaji T, Ideta R, Inomata Y, Tanihara H.
    Acta Ophthalmol; 2018 May; 96(3):e393-e398. PubMed ID: 29220114
    [Abstract] [Full Text] [Related]

  • 16. Aflibercept therapy in eyes with neovascular age-related macular degeneration and its effect on choroidal thickness.
    Sariyeva Ismayılov A, Esen E, Sızmaz S, Demircan AN.
    Clin Exp Optom; 2019 Nov; 102(6):617-620. PubMed ID: 30793798
    [Abstract] [Full Text] [Related]

  • 17. Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Pachychoroid Neovasculopathy.
    Cho HJ, Jung SH, Cho S, Han JO, Park S, Kim JW.
    J Ocul Pharmacol Ther; 2019 Apr; 35(3):174-181. PubMed ID: 30807236
    [Abstract] [Full Text] [Related]

  • 18. Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration: A Prospective Study.
    Maruko I, Ogasawara M, Yamamoto A, Itagaki K, Hasegawa T, Arakawa H, Nakayama M, Koizumi H, Okada AA, Sekiryu T, Iida T.
    Ophthalmol Retina; 2020 Aug; 4(8):767-776. PubMed ID: 32417356
    [Abstract] [Full Text] [Related]

  • 19. Development of Age-Related Macular Degeneration (AMD) in the Fellow Eye of Patients with AMD Treated by Treat-and-Extend Intravitreal Therapy with Aflibercept.
    Mimura K, Matsumoto H, Morimoto M, Akiyama H.
    Ophthalmologica; 2018 Aug; 239(2-3):121-127. PubMed ID: 29169154
    [Abstract] [Full Text] [Related]

  • 20. Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study.
    Kim JH, Lee TG, Chang YS, Kim CG, Cho SW.
    Br J Ophthalmol; 2016 Dec; 100(12):1634-1639. PubMed ID: 26951770
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.